| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2018 | ALKS Alkermes Plc. | Anstice David W | Director | Sell | 8,787 | $35.59 | $312,710.24 | -4.2% | |
| Dec 11, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Koo Richard | Director | Sell | 29,278 | $21.32 | $624,075.21 | -10.8% | |
| Dec 10, 2018 | LLY Eli Lilly & Co | O'Neill Myles | SVP &Pres., Mfg. Operations | Sell | 25,000 | $112.92 | $2,822,959.00 | -18.9% | |
| Dec 10, 2018 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Buy | 1,000 | $7.78 | $7,780.00 | - | |
| Dec 10, 2018 | ORGO Organogenesis Holdings Inc. | Avista Capital Managing Member Iv, LLC | 10% Owner | Buy | 6,538,732 | $0.00 | - | +72.5% | |
| Dec 10, 2018 | AQST Aquestive Therapeutics, Inc. | Barber Daniel77 | Svp-chief Strategy/ Dev Officer | Buy | 1,000 | $8.00 | $8,000.00 | +1.0% | |
| Dec 10, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shohet Stephen B. | Director | Sell | 58,557 | $21.72 | $1,271,781.92 | -65.6% | |
| Dec 10, 2018 | BCRX Biocryst Pharmaceuticals Inc | Powell Lynne | Senior VP - CCO | Sell | 4,000 | $9.06 | $36,240.00 | -100% | |
| Dec 7, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mueller Peter | Director | Buy | 8,795 | $5.01 | $44,045.05 | +1.5% | |
| Dec 7, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $4.59 | $844,192.00 | -0.5% | |
| Dec 7, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Lee Howard | Director | Sell | 29,278 | $21.67 | $634,463.59 | -4.5% | |
| Dec 6, 2018 | AQST Aquestive Therapeutics, Inc. | Maxwell John T. | Svp-chief Financial Officer | Buy | 5,000 | $8.87 | $44,350.00 | +3.4% | |
| Dec 6, 2018 | TXMD Therapeuticsmd, Inc. | Cartwright Daniel A | CFO | Sell | 40,000 | $4.57 | $182,800.00 | -50.0% | |
| Dec 6, 2018 | IRWD Ironwood Pharmaceuticals Inc | Olanoff Lawrence S | Director | Sell | 2,000 | $12.47 | $24,940.00 | -4.8% | |
| Dec 6, 2018 | IRWD Ironwood Pharmaceuticals Inc | McHugh Julie53 | Director | Sell | 1,500 | $12.46 | $18,690.00 | -1.6% | |
| Dec 6, 2018 | DVAX Dynavax Technologies Corp | Cano Francis | Director | Sell | 2,000 | $10.47 | $20,942.00 | -100% | |
| Dec 6, 2018 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Buy | 2,000 | $8.69 | $17,380.00 | +0.2% | |
| Dec 6, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 258,000 | $4.77 | $1,231,692.00 | -8.1% | |
| Dec 4, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 15,500 | $119.00 | $1,844,535.65 | - | |
| Dec 4, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 3,922 | $9.45 | $37,062.90 | -2.9% | |
| Dec 4, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO, President, Secretary | Buy | 1,000 | $5.12 | $5,120.00 | +22.2% | |
| Dec 4, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mueller Peter | Director | Buy | 4,007 | $5.13 | $20,544.17 | +0.5% | |
| Dec 4, 2018 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Buy | 900 | $5.21 | $4,692.24 | +38.3% | |
| Dec 4, 2018 | JNJ Johnson & Johnson | Fasolo Peter61 | Exec VP, Chief Hr Officer | Sell | 166,695 | $146.41 | $24,405,240.86 | -51.6% | |
| Dec 3, 2018 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $4.64 | $46,400.00 | -1.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.